Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Horizon Pharma grants Mallinckrodt LLC US co-promote rights to Duexis; deal terminated

Executive Summary

Horizon Pharma Inc. (therapies for pain and inflammation) has granted Covidien Ltd.’s pharmaceutical subsidiary Mallinckrodt LLC US co-promotion rights to Duexis (ibuprofen and famotidine) through the end of 2014, with potential for the parties to extend the agreement.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Marketing (Licensing)

Related Companies